{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Duarte&page=18&state=California", "query": { "state": "California", "city": "Duarte", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 1196, "total_pages": 120, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Duarte&page=19&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Duarte&page=17&state=California&page_size=10" }, "source": "local", "last_synced_at": "2026-10-16T00:43:38.748Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07265674", "title": "A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Biliary Tract Cancer", "Biliary Tract Cancer (BTC)" ], "interventions": [ { "name": "Nanvuranlat", "type": "DRUG" }, { "name": "Physician's Best Choice", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "J-Pharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": "2026-05-11", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-14T03:52:20.186Z", "location_count": 18, "location_summary": "Duarte, California • Orange, California • Santa Monica, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07265674" }, { "nct_id": "NCT07011719", "title": "Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Casdatifan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 720, "start_date": "2025-09-08", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-13T18:51:20.473Z", "location_count": 46, "location_summary": "Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 40 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07011719" }, { "nct_id": "NCT06763341", "title": "A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "PCNA Inhibitor AOH1996", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2025-07-30", "completion_date": "2027-01-16", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-07T00:26:38.054Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06763341" }, { "nct_id": "NCT05877599", "title": "A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Myeloid Neoplasms (AML/MDS)", "Non-small Cell Lung Cancer", "Other Solid Tumors", "Ovarian Cancer", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "NT-175", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2023-07-12", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-14T08:17:19.562Z", "location_count": 20, "location_summary": "Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05877599" }, { "nct_id": "NCT03802695", "title": "A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Mixed Phenotype Acute Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "OrcaGraft (Orca-Q)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Orca Biosystems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "12 Years to 78 Years" }, "enrollment_count": 300, "start_date": "2019-04-08", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-13T18:37:05.067Z", "location_count": 12, "location_summary": "Duarte, California • Sacramento, California • Stanford, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03802695" }, { "nct_id": "NCT07594106", "title": "REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma (ccRCC)", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "REGN15505", "type": "DRUG" }, { "name": "REGN15505+Cemiplimab", "type": "DRUG" }, { "name": "REGN15505+REGN4336", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2026-07-20", "completion_date": "2030-10-27", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-15T17:52:53.076Z", "location_count": 6, "location_summary": "Goodyear, Arizona • Duarte, California • Tampa, Florida + 3 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Zion", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07594106" }, { "nct_id": "NCT07277413", "title": "A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of Esophagus", "Biliary Tract Carcinoma", "Bladder Cancer", "Gastric Adenocarcinoma", "Gastroesophageal Cancer (GC)", "Mesothelioma", "NSCLC Adenocarcinoma", "Non-Small Cell Lung Cancer NSCLC", "Pancreatic Cancer", "Peritoneal Mesothelioma", "Pleural Mesothelioma", "Squamous Cell Car. - Esophagus", "Urothelial Carcinoma (UC)" ], "interventions": [ { "name": "IDE397", "type": "DRUG" }, { "name": "IDE892", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2026-03-04", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-13T18:58:33.900Z", "location_count": 23, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07277413" }, { "nct_id": "NCT07277231", "title": "A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2026-01-22", "completion_date": "2031-11", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-16T00:43:38.748Z", "location_count": 22, "location_summary": "Duarte, California • Orange, California • Palo Alto, California + 19 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07277231" }, { "nct_id": "NCT07226349", "title": "A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BG-75098", "type": "DRUG" }, { "name": "BGB-43395", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2025-12-11", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-14T11:59:29.686Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Duarte, California • New Haven, Connecticut + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226349" }, { "nct_id": "NCT07221253", "title": "A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Biliary Tract Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Gemcitabine/Cisplatin", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1100, "start_date": "2025-12-04", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-14T01:07:57.574Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221253" } ] }